1. Home
  2. TYRA vs CRESY Comparison

TYRA vs CRESY Comparison

Compare TYRA & CRESY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TYRA
  • CRESY
  • Stock Information
  • Founded
  • TYRA 2018
  • CRESY 1936
  • Country
  • TYRA United States
  • CRESY Argentina
  • Employees
  • TYRA N/A
  • CRESY N/A
  • Industry
  • TYRA Biotechnology: Pharmaceutical Preparations
  • CRESY Real Estate
  • Sector
  • TYRA Health Care
  • CRESY Finance
  • Exchange
  • TYRA Nasdaq
  • CRESY Nasdaq
  • Market Cap
  • TYRA 812.7M
  • CRESY 815.5M
  • IPO Year
  • TYRA 2021
  • CRESY 1997
  • Fundamental
  • Price
  • TYRA $14.00
  • CRESY $12.23
  • Analyst Decision
  • TYRA Strong Buy
  • CRESY
  • Analyst Count
  • TYRA 5
  • CRESY 0
  • Target Price
  • TYRA $31.00
  • CRESY N/A
  • AVG Volume (30 Days)
  • TYRA 219.5K
  • CRESY 368.0K
  • Earning Date
  • TYRA 11-07-2024
  • CRESY 02-07-2025
  • Dividend Yield
  • TYRA N/A
  • CRESY 8.12%
  • EPS Growth
  • TYRA N/A
  • CRESY N/A
  • EPS
  • TYRA N/A
  • CRESY N/A
  • Revenue
  • TYRA N/A
  • CRESY $751,941,316.00
  • Revenue This Year
  • TYRA N/A
  • CRESY N/A
  • Revenue Next Year
  • TYRA N/A
  • CRESY N/A
  • P/E Ratio
  • TYRA N/A
  • CRESY N/A
  • Revenue Growth
  • TYRA N/A
  • CRESY N/A
  • 52 Week Low
  • TYRA $11.24
  • CRESY $6.56
  • 52 Week High
  • TYRA $29.60
  • CRESY $14.23
  • Technical
  • Relative Strength Index (RSI)
  • TYRA 32.68
  • CRESY 47.97
  • Support Level
  • TYRA $14.65
  • CRESY $13.12
  • Resistance Level
  • TYRA $15.55
  • CRESY $14.11
  • Average True Range (ATR)
  • TYRA 0.72
  • CRESY 0.76
  • MACD
  • TYRA 0.02
  • CRESY -0.24
  • Stochastic Oscillator
  • TYRA 3.12
  • CRESY 37.36

About TYRA Tyra Biosciences Inc.

Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology The Company's in-house precision medicine platform, SNÅP, enables rapid and precise drug design through iterative molecular SNAPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. Its lead product candidate is TYRA 300, an FGFR3 selective inhibitor with an initial focus on patients with metastatic urothelial carcinoma of the bladder and urinary tract (mUC).

About CRESY Cresud S.A.C.I.F. y A.

Cresud SACIF y A is engaged in agricultural business and urban properties and investment business. Under its agricultural business the company produces oilseed grains and cereals, sugar cane and meat. The Agricultural business of the company is further comprised of four reportable segments which are Agricultural production, Land transformation and Sales, Corporate and Other segments. The company participates in the real estate business in Argentina through its subsidiary IRSA. The real estate business is further comprised of five reportable segments, namely Shopping Malls, Offices, Sales and Developments, Hotels and others.

Share on Social Networks: